TerminatedPHASE1, PHASE2NCT04326283

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Genuv Inc.
Principal Investigator
Byoung Joon Kim
Samsung Medical Center, Seoul, Republic of Korea
Intervention
Trametinib (0.5 mg)(drug)
Enrollment
23 enrolled
Eligibility
19-75 years · All sexes
Timeline
20202023

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04326283 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials